亚克隆NT5C2突变与儿童急性淋巴细胞白血病复发后不良结局相关
该研究在ALL-REZ BFM 2002试验的455例复发B细胞前体急性淋巴细胞白血病患者中,通过测序和等位基因特异性实时PCR分析NT5C2突变。75例(16.5%)复发携带NT5C2突变,其中三分之二为亚克隆突变。亚克隆NT5C2突变在多变量分析中与无事件生存率降低独立相关,且与复发治疗无反应率升高相关。
要点
- 复发ALL中NT5C2突变发生率16.5%,三分之二为亚克隆突变。
- 亚克隆NT5C2突变独立关联无事件生存率降低(HR 1.89)。
- 亚克隆NT5C2突变者复发治疗无反应率32%,高于克隆突变12%和野生型9%。
核心结论
- 亚克隆NT5C2突变定义了一类治疗失败高风险的ALL复发,但其作用复杂,超越突变NT5C2作为可靶向驱动因素的角色。
研究设计与样本
- 研究分析了ALL-REZ BFM 2002复发试验中455例复发B细胞前体ALL患者,采用测序和敏感等位基因特异性实时PCR检测NT5C2突变。
主要发现
- 455例复发中75例(16.5%)检出110个NT5C2突变,三分之二复发携带亚克隆突变,三分之一携带克隆突变。
- 克隆和亚克隆NT5C2突变患者复发后无事件生存率分别为19%和25%,低于无突变者的53%(P < .001)。
- 多变量分析中仅亚克隆NT5C2突变与无事件生存率降低相关(HR 1.89,95%CI 1.28-2.69,P = .001)。
- 亚克隆、克隆和野生型患者复发治疗无反应率分别为32%、12%和9%(P < .001)。
- 33个亚克隆NT5C2突变中27个(82%)在无反应或第二次复发时变为不可测,14例患者中10例(71%)在复发诱导治疗后即不可测。
关键数值与推荐
- 亚克隆NT5C2突变多变量分析HR 1.89(95%CI 1.28-2.69,P = .001)。
- 复发治疗无反应率:亚克隆32%,克隆12%,野生型9%(P < .001)。
- 复发后无事件生存率:克隆19%,亚克隆25%,无突变53%(P < .001)。
临床怎么用
- 对复发B细胞前体ALL患者进行敏感的NT5C2突变前瞻性检测,有助于识别治疗失败高风险亚型。
- 亚克隆NT5C2突变患者复发治疗无反应风险高,需考虑强化或替代治疗策略。
局限性
- 原文未报告具体局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activating mutations in cytosolic 5'-nucleotidase II (NT5C2) are considered to drive relapse formation in acute lymphoblastic leukemia (ALL) by conferring purine analog resistance. To examine the clinical effects of NT5C2 mutations in relapsed ALL, we analyzed NT5C2 in 455 relapsed B-cell precursor ALL patients treated within the ALL-REZ BFM 2002 relapse trial using sequencing and sensitive allele-specific real-time polymerase chain reaction. We detected 110 NT5C2 mutations in 75 (16.5%) of 455 B-cell precursor ALL relapses. Two-thirds of relapses harbored subclonal mutations and only one-third harbored clonal mutations. Event-free survival after relapse was inferior in patients with relapses with clonal and subclonal NT5C2 mutations compared with those without (19% and 25% vs 53%, P < .001). However, subclonal, but not clonal, NT5C2 mutations were associated with reduced event-free survival in multivariable analysis (hazard ratio, 1.89; 95% confidence interval, 1.28-2.69; P = .001) and with an increased rate of nonresponse to relapse treatment (subclonal 32%, clonal 12%, wild type 9%, P < .001). Nevertheless, 27 (82%) of 33 subclonal NT5C2 mutations became undetectable at the time of nonresponse or second relapse, and in 10 (71%) of 14 patients subclonal NT5C2 mutations were undetectable already after relapse induction treatment. These results show that subclonal NT5C2 mutations define relapses associated with high risk of treatment failure in patients and at the same time emphasize that their role in outcome is complex and goes beyond mutant NT5C2 acting as a targetable driver during relapse progression. Sensitive, prospective identification of NT5C2 mutations is warranted to improve the understanding and treatment of this aggressive ALL relapse subtype.
引用
- Barz MJ, Hof J, Groeneveld-Krentz S, et al. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. Blood. 2020. PMID: 31971569. doi:10.1182/blood.2019002499
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。